Supernus Pharmaceuticals, Inc. (SUPN) Stock Price & Analysis
Supernus Pharmaceuticals, Inc. (SUPN) rose 2.65% to USD 45.66 as of June 10, 2026 at 03:38 UTC, according to Nexqual real-time market data.
SUPN last closed at USD 44.48; the session ranged USD 44.7–45.74 on volume of 358,906 shares. Market capitalization is $2.65B, with a 52-week range of USD 30.83–59.68 (NGM). Source: Nexqual, June 10, 2026 at 03:38 UTC.
Key Statistics (as of June 10, 2026 at 03:38 UTC)
| Price | USD 45.66 |
|---|---|
| Change | ▲ 2.65% (up) |
| Previous Close | USD 44.48 |
| Open | USD 44.86 |
| Day Range | USD 44.7 – 45.74 |
| 52-Week Range | USD 30.83 – 59.68 |
| Volume | 358,906 shares |
| Market Cap | $2.65B |
| Exchange | NGM |
Technical Analysis (SUPN)
Nexqual's technical model rates SUPN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.42 (neutral) |
| vs SMA50 | Below (USD 48.99) |
| MACD | -1.37 (negative) |
Analyst Ratings (SUPN)
Wall Street analysts rate SUPN "Strong Buy" based on 6 analysts, with a mean price target of USD 62.83 (range USD 55–66), per Nexqual as of June 10, 2026 at 03:38 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 62.83 |
| High Target | USD 66 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (SUPN)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD 0.46 |
| Revenue Estimate | $205.63M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.21 vs est 0.28 ▼ miss |
| 2025-12-31 | USD 0.88 vs est 0.28 ▲ beat |
| 2025-09-30 | USD 0.61 vs est 0.82 ▼ miss |
| 2025-06-30 | USD 0.91 vs est 0.47 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Financials & Fundamentals (SUPN)
| Total Revenue | $776.83M |
|---|---|
| Revenue Growth (YoY) | +38.60% |
| Gross Margin | +74.13% |
| Operating Margin | -3.58% |
| Profit Margin | -3.74% |
| ROE | -2.75% |
| Debt / Equity | 3.8 |
| Current Ratio | 1.96 |
| Total Cash | $384.24M |
| Total Debt | $40.90M |
| Free Cash Flow | $132.62M |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Financial Health Score (SUPN)
Nexqual rates Supernus Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 03:38 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 74%, operating -4% |
| Balance Sheet | Strong — $384M cash vs $41M debt, net cash position |
| Cash Flow | Strong — FCF $133M, 18% margin |
| Efficiency | Critical — ROE -3%, ROA 1.1% |
Ownership (SUPN)
| Insider Ownership | +4.46% |
|---|---|
| Institutional Ownership | +103.86% |
| Shares Outstanding | 58.04M |
| Float | 52.12M |
| Short % of Float | +11.47% |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
Leadership (SUPN)
Supernus Pharmaceuticals, Inc. is led by Jack A. Khattar (age 64), Founder, President, CEO, Secretary & Director, per Nexqual as of June 10, 2026 at 03:38 UTC.
| Founder, President, CEO, Secretary & Director | Jack A. Khattar (age 64) |
|---|---|
| Senior VP & CFO | Timothy C. Dec (age 66) |
| Chief Scientific Officer & Senior VP of Intellectual Property | Padmanabh P. Bhatt (age 68) |
| Senior VP & Chief Technology Operations Officer | Frank Mottola (age 53) |
| Senior Vice President of Sales | Taylor Raiford |
Major Backers & Investors (SUPN)
Notable institutional backers of Supernus Pharmaceuticals, Inc. include Millennium Management, Nomura Asset Management International Inc, Armistice Capital, LLC, according to Nexqual as of June 10, 2026 at 03:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Millennium Management | 5.71% |
| Nomura Asset Management International Inc | 3.51% |
| Armistice Capital, LLC | 3.27% |
| Renaissance Technologies | 2.94% |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.62% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.41% |
| Vanguard Group | 18.76% |
| State Street | 4.84% |
| Dimensional Fund Advisors | 3.97% |
| Geode Capital | 2.8% |
Source: Nexqual, June 10, 2026 at 03:38 UTC.
From Supernus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.
- It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
- It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea.
- In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCRX | Pacira BioSciences, Inc. | USD 23.21 | ▲ 2.02% |
| INVA | Innoviva, Inc. | USD 22.54 | ▲ 0.09% |
| CORT | Corcept Therapeutics Incorporat | USD 77.49 | ▲ 6.71% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 11.35 | ▲ 0.62% |
| IRWD | Ironwood Pharmaceuticals, Inc. | USD 3.22 | ▼ 2.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:38 UTC. This page is informational and not investment advice.